Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility

Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility

Abstract Background About half of heart failure (HF) patients, while having preserved left ventricular function, suffer from diastolic dysfunction (so‐called HFpEF). No specific therapeutics are available for HFpEF in contrast to HF where reduced ejection fractions (HFrEF) can be treated pharmacolog...

Full description

Bibliographic Details
Main Authors: Volker Adams, Antje Schauer, Antje Augstein, Virginia Kirchhoff, Runa Draskowski, Anett Jannasch, Keita Goto, Gemma Lyall, Anita Männel, Peggy Barthel, Norman Mangner, Ephraim B. Winzer, Axel Linke, Siegfried Labeit
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Journal of Cachexia, Sarcopenia and Muscle
Subjects:
HFpEF
ZSF1
MuRF1
Diastolic dysfunction
Skeletal muscle dysfunction
Muscle atrophy
Online Access:https://doi.org/10.1002/jcsm.12968

Internet

https://doi.org/10.1002/jcsm.12968

Similar Items